Detection of G-quadruplex DNA Methylation in Cancer

NCT06537063 | Withdrawn

• 1 other identifier: YX202401
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the early diagnosis value of G-quadruplex DNA methylation in patients with cancer.

Conditions

Cancer; DNA G-quadruplex; Methylation; Cell-free DNA

Outcome Measures

Primary Outcomes (1)

• G-quadruplex DNAm score

  Detection of DNAm around G-quadruplex loci in cell-free DNA from blood.

  2024.04.30-2024.09.30

Study Arms (1)

Asymptomatic population

Asymptomatic medical examination population.

Other: G4 DNAm test

Interventions

G4 DNAm test OTHER

Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.

Asymptomatic population

Eligibility Criteria

• Age: 42 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Healthy volunteers, aged 42 years or older, who are asymptomatic as determined by medical examination and willing to participate voluntarily in the study with signed informed consent.

You may qualify if:

• Healthy volunteers identified as asymptomatic during medical examination;
• Age≥42 years old;
• Voluntarily participate in this study and sign the informed consent.

You may not qualify if:

• History of malignancy or having achieved complete remission following tumor surgery;
• Certain autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, Crohn's disease, IgA nephropathy, myasthenia gravis, dermatomyositis, immune thrombocytopenic purpura, etc.);
• Pregnancy;
• Acute trauma (including surgical procedures), sudden onset organ failure (e.g., resulting from a car accident, fulminant hepatic failure, acute pancreatitis, severe pneumonia due to influenza virus), or diagnosis of sepsis;
• Previous receipt of allogeneic blood transfusion, transplant surgery, or allogeneic cell therapy;
• Volunteers who cannot provide informed consent.

Sponsors & Collaborators

• Zhongnan Hospital: lead

Study Sites (1)

Hubei Locations

Wuhan, Hubei, 430071, China

Location

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: July 31, 2024
• First Posted: August 5, 2024
• Study Start: April 30, 2024
• Primary Completion: September 30, 2024
• Study Completion: December 30, 2024
• Last Updated: January 7, 2025

Record last verified: 2024-07

Locations

CN (1)